<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="713">
  <stage>Registered</stage>
  <submitdate>7/09/2005</submitdate>
  <approvaldate>7/09/2005</approvaldate>
  <nctid>NCT00159640</nctid>
  <trial_identification>
    <studytitle>Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia</studytitle>
    <scientifictitle>A Multi-Center, Randomized, Double Blind, Dose-Response, Placebo And Gabapentin Controlled Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A4451006</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PD-217,014

Treatment: drugs: PD-217,014


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To characterise the effectiveness of PD-217,014 in the treatment of chronic pain. A numerical pain intensity rating scale is used to assess pain and a mean endpoint (week 4) pain score change from baseline is calculated.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>- Assess the effect of PD-217,014 on responder rate based on the primary endpoint, mean endpoint sleep interference score and the SF-McGill questionnaire (change from baseline to week 4)</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients must have pain present for more than 3 months after the healing of shingles
             skin rash.

          -  Patients at screening must have a score &gt;=40 mm on the pain visual analogue scale.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with poor renal function.

          -  Patients with other severe pain, that may impair the self-assessment of the pain due
             to shingles.

          -  Patients with abnormal electrocardiogram.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,WA</recruitmentstate>
    <hospital>Pfizer Investigational Site - Warrawong</hospital>
    <hospital>Pfizer Investigational Site - Westmead</hospital>
    <hospital>Pfizer Investigational Site - Kippa Ring</hospital>
    <hospital>Pfizer Investigational Site - Maroochydore</hospital>
    <hospital>Pfizer Investigational Site - Bedford Park</hospital>
    <hospital>Pfizer Investigational Site - Perth</hospital>
    <hospital>Pfizer Investigational Site - Woodville</hospital>
    <postcode> - Warrawong</postcode>
    <postcode> - Westmead</postcode>
    <postcode> - Kippa Ring</postcode>
    <postcode> - Maroochydore</postcode>
    <postcode> - Bedford Park</postcode>
    <postcode> - Perth</postcode>
    <postcode> - Woodville</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ceske Budejovice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>CZ-Praha 8</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Plzen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Arnhem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Breda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Kampen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Roosendaal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Stadskanaal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Granada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hants</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Northants</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country />
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the effectiveness of PD-217,014 in the treatment of
      chronic pain following a shingles infection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00159640</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>